Upadacitinib for treating giant cell arteritis [ID6299]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: 25 February 2026
Benralizumab for treating relapsing or refractory eosinophilic granulomatosis with polyangiitis [ID6266]Status:In developmentProgramme:Technology appraisal guidanceExpected publication date: TBC